NNVC beat EPS expectations by 6.86%
Oct 04, 2024, 10:35 AM
0.00%
What does NNVC do
NanoViricides, based in Shelton, Connecticut, develops nanomedicine drugs targeting enveloped viruses, with lead candidates NV-CoV-2 for COVID-19 and NV-HHV-1 for Shingles. The company went public on August 12, 2004.
NanoViricides (NNVC) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, NanoViricides's actual EPS was -$0.19, beating the estimate of -$0.20 per share, resulting in a 6.86% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.